Literature DB >> 17510433

Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.

Olivier Preynat-Seauve1, Emmanuel Contassot, Prisca Schuler, Vincent Piguet, Lars E French, Bertrand Huard.   

Abstract

Metastases often develop in lymphoid organs. However, the immunologic mechanism allowing such invasion is not known because these organs are considered to be hostile to tumor cells. Here, we analyzed the interactions between tumor cells and CD8(+) T cells in such lymphoid organs. Tumor cells implanted into lymph nodes were able to induce tumor-specific cytotoxic CD8(+) T-cell responses, conducting to tumor rejection, in contrast to primary extralymphatic tumors rapidly anergizing T cells in draining lymph nodes (DLN) via a cross-presentation process. This abortive CD8(+) T-cell response to extralymphatic tumor is independent of the subcellular localization of antigen in tumor cells and is consistent with a lack of CD4(+) T-cell help. Notably, this anergy was potent enough to allow successful DLN implantation of tumor cells. Such distant cross-tolerization of tumor-specific CD8(+) T cells may be a determinant permissive event leading to invasion of DLN. In this situation, metastatic tumor cells do not need to down-regulate their immunogenicity to spread.

Entities:  

Mesh:

Year:  2007        PMID: 17510433     DOI: 10.1158/0008-5472.CAN-06-4494

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; B Manfroi; A Zeller; I Dunand-Sauthier; B Bogen; B Huard
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

Review 3.  Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity.

Authors:  Melody A Swartz; Amanda W Lund
Journal:  Nat Rev Cancer       Date:  2012-02-24       Impact factor: 60.716

Review 4.  The lymph node pre-metastatic niche.

Authors:  Jonathan P Sleeman
Journal:  J Mol Med (Berl)       Date:  2015-11       Impact factor: 4.599

5.  Preparation of myeloid derived suppressor cells (MDSC) from naive and pancreatic tumor-bearing mice using flow cytometry and automated magnetic activated cell sorting (AutoMACS).

Authors:  Nadine Nelson; Karoly Szekeres; Denise Cooper; Tomar Ghansah
Journal:  J Vis Exp       Date:  2012-06-18       Impact factor: 1.355

Review 6.  The lymph node microenvironment and its role in the progression of metastatic cancer.

Authors:  Ethel R Pereira; Dennis Jones; Keehoon Jung; Timothy P Padera
Journal:  Semin Cell Dev Biol       Date:  2015-01-22       Impact factor: 7.727

7.  B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.

Authors:  David J DiLillo; Koichi Yanaba; Thomas F Tedder
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

Review 8.  Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.

Authors:  Haley du Bois; Taylor A Heim; Amanda W Lund
Journal:  Sci Immunol       Date:  2021-09-03

9.  Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.

Authors:  Feng Qiu; Kyle W Becker; Frances C Knight; Jessalyn J Baljon; Sema Sevimli; Daniel Shae; Pavlo Gilchuk; Sebastian Joyce; John T Wilson
Journal:  Biomaterials       Date:  2018-07-30       Impact factor: 12.479

Review 10.  Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.

Authors:  Michael Yamakawa; Susan J Doh; Samuel M Santosa; Mario Montana; Ellen C Qin; Hyunjoon Kong; Kyu-Yeon Han; Charles Yu; Mark I Rosenblatt; Andrius Kazlauskas; Jin-Hong Chang; Dimitri T Azar
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.